Covered recipient · General Payments record
ELIZABETH H MUIJE
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Women's Health
General Payments · PY2021–2024
$1,263.64
- Reported across 70 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $335.86 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Astellas Pharma US Inc | $90.52 | 4 |
| ABBVIE INC. | $74.23 | 4 |
| Biogen, Inc. | $60.94 | 4 |
| Organon LLC | $50.14 | 3 |
| SHIELD THERAPEUTICS INC | $40.54 | 2 |
| Novo Nordisk AS | $19.49 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $18.69 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107704126 | CMS |
| ABBVIE INC. | $16.33 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107704128 | CMS |
| ABBVIE INC. | $20.50 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107704130 | CMS |
| ABBVIE INC. | $18.71 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107704132 | CMS |
| Astellas Pharma US Inc | $25.09 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139491694 | CMS |
| Astellas Pharma US Inc | $21.23 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139519887 | CMS |
| Astellas Pharma US Inc | $22.82 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139467464 | CMS |
| Astellas Pharma US Inc | $21.38 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139533186 | CMS |
| Biogen, Inc. | $18.80 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104875452 | CMS |
| Biogen, Inc. | $14.02 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104856014 | CMS |
| Biogen, Inc. | $14.70 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104829492 | CMS |
| Biogen, Inc. | $13.42 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104811481 | CMS |
| Novo Nordisk Inc | $19.49 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100621046 | CMS |
| Organon Llc | $16.86 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136211333 | CMS |
| Organon Llc | $17.06 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136211329 | CMS |
| Organon Llc | $16.22 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136211331 | CMS |
| SHIELD THERAPEUTICS INC | $19.85 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150145672 | CMS |
| SHIELD THERAPEUTICS INC | $20.69 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150154800 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.